Movatterモバイル変換


[0]ホーム

URL:


GB0225535D0 - Medicinal compounds - Google Patents

Medicinal compounds

Info

Publication number
GB0225535D0
GB0225535D0GBGB0225535.4AGB0225535AGB0225535D0GB 0225535 D0GB0225535 D0GB 0225535D0GB 0225535 AGB0225535 AGB 0225535AGB 0225535 D0GB0225535 D0GB 0225535D0
Authority
GB
United Kingdom
Prior art keywords
medicinal compounds
medicinal
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0225535.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group LtdfiledCriticalGlaxo Group Ltd
Priority to GBGB0225535.4ApriorityCriticalpatent/GB0225535D0/en
Publication of GB0225535D0publicationCriticalpatent/GB0225535D0/en
Priority to AU2003279338Aprioritypatent/AU2003279338A1/en
Priority to PCT/EP2003/012194prioritypatent/WO2004039762A1/en
Ceasedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

GBGB0225535.4A2002-11-012002-11-01Medicinal compoundsCeasedGB0225535D0 (en)

Priority Applications (3)

Application NumberPriority DateFiling DateTitle
GBGB0225535.4AGB0225535D0 (en)2002-11-012002-11-01Medicinal compounds
AU2003279338AAU2003279338A1 (en)2002-11-012003-10-30Phenethanolamine derivatives for the treatment of respiratory diseases
PCT/EP2003/012194WO2004039762A1 (en)2002-11-012003-10-30Phenethanolamine derivatives for the treatment of respiratory diseases

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
GBGB0225535.4AGB0225535D0 (en)2002-11-012002-11-01Medicinal compounds

Publications (1)

Publication NumberPublication Date
GB0225535D0true GB0225535D0 (en)2002-12-11

Family

ID=9947057

Family Applications (1)

Application NumberTitlePriority DateFiling Date
GBGB0225535.4ACeasedGB0225535D0 (en)2002-11-012002-11-01Medicinal compounds

Country Status (3)

CountryLink
AU (1)AU2003279338A1 (en)
GB (1)GB0225535D0 (en)
WO (1)WO2004039762A1 (en)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2003024396A2 (en)2001-09-172003-03-27Glaxo Group LimitedDry powder medicament formulations
GB0316290D0 (en)2003-07-112003-08-13Glaxo Group LtdNovel compounds
GB0401334D0 (en)2004-01-212004-02-25Novartis AgOrganic compounds
GB0411056D0 (en)2004-05-182004-06-23Novartis AgOrganic compounds
AR049384A1 (en)2004-05-242006-07-26Glaxo Group Ltd PURINA DERIVATIVES
GB0418045D0 (en)2004-08-122004-09-15Glaxo Group LtdCompounds
KR20070053205A (en)2004-09-172007-05-23에자이 알앤드디 매니지먼트 가부시키가이샤 Medicinal composition
GT200500281A (en)2004-10-222006-04-24Novartis Ag ORGANIC COMPOUNDS.
GB0424284D0 (en)2004-11-022004-12-01Novartis AgOrganic compounds
GB0426164D0 (en)2004-11-292004-12-29Novartis AgOrganic compounds
ATE517908T1 (en)2005-01-102011-08-15Glaxo Group Ltd ANDROSTAN-17-ALPHA-CARBONATE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY CONDITIONS
TWI389690B (en)2005-03-252013-03-21Glaxo Group LtdNovel compounds
GB0507577D0 (en)2005-04-142005-05-18Novartis AgOrganic compounds
GB0510390D0 (en)2005-05-202005-06-29Novartis AgOrganic compounds
GB0514809D0 (en)2005-07-192005-08-24Glaxo Group LtdCompounds
GB0516313D0 (en)2005-08-082005-09-14Argenta Discovery LtdAzole derivatives and their uses
EP2281813A1 (en)2005-08-082011-02-09Pulmagen Therapeutics (Synergy) LimitedBicyclo[2.2.1]hept-7-ylamine derivatives and their uses
MY144906A (en)2005-10-212011-11-30Novartis AgHuman antibodies against il13 and therapeutic uses
PE20071068A1 (en)2005-12-202007-12-13Glaxo Group Ltd 3- (4 - {[4- (4 - {[3- (3,3-DIMETHYL-1-PIPERIDINYL) PROPYL] OXY} PHENYL) -1-PIPERIDINYL] CARBONYL} -1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID, SALTS OF THE SAME, AS ANTAGONISTS OF THE H1 AND H3 RECEPTORS
GB0601951D0 (en)2006-01-312006-03-15Novartis AgOrganic compounds
AR060536A1 (en)2006-04-202008-06-25Glaxo Group Ltd GLUCOCORTICOID RECEPTOR AGONIST AND PHARMACEUTICAL COMPOSITIONS
JP5373599B2 (en)2006-04-212013-12-18ノバルティス アーゲー Purine derivatives for use as adenosine A2A receptor agonists
GB0611587D0 (en)2006-06-122006-07-19Glaxo Group LtdNovel compounds
TW200817006A (en)2006-06-232008-04-16Smithkline Beecham CorpIL-8 receptor antagonist
ATE504586T1 (en)2006-08-012011-04-15Glaxo Group Ltd PYRAZOLOA3,4-BUPYRIDINE COMPOUNDS AND THEIR USE AS PDE4 INHIBITORS
KR20090075714A (en)2006-10-302009-07-08노파르티스 아게 Heterocyclic compounds as anti-inflammatory agents
MX2009007476A (en)2007-01-102009-07-22Irm LlcCompounds and compositions as channel activating protease inhibitors.
PE20081889A1 (en)2007-03-232009-03-05Smithkline Beecham Corp INDOL CARBOXAMIDES AS INHIBITORS OF IKK2
CN101687851B (en)2007-05-072013-02-27诺瓦提斯公司Organic compounds
EA017919B1 (en)2007-12-102013-04-30Новартис АгPyrazine-2 carboxamide derivatives for treating diseases which respond to the blocade of the epithelial sodium channels
PT2231642E (en)2008-01-112014-03-12Novartis AgPyrimidines as kinase inhibitors
EP2285803A4 (en)2008-05-232011-10-05Amira Pharmaceuticals Inc5-lipoxygenase-activating protein inhibitor
US8163743B2 (en)2008-06-052012-04-24GlaxoGroupLimited4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
EA201001848A1 (en)2008-06-102011-08-30Новартис Аг DERIVATIVES OF PIRAZINE AS EPITELIAL SODIUM CHANNEL BLOCKS
US8236786B2 (en)2008-08-072012-08-07Pulmagen Therapeutics (Inflammation) LimitedRespiratory disease treatment
WO2010076553A1 (en)2008-12-302010-07-08Dr. Reddy's Laboratories LtdSulfonamide compounds for the treatment of respiratory disorders
EP2391366B1 (en)2009-01-292012-11-28Novartis AGSubstituted benzimidazoles for the treatment of astrocytomas
WO2010094643A1 (en)2009-02-172010-08-26Glaxo Group LimitedQuinoline derivatives and their uses for rhinitis and urticaria
WO2010102958A1 (en)2009-03-092010-09-16Glaxo Group Limited4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
WO2010102968A1 (en)2009-03-102010-09-16Glaxo Group LimitedIndole derivatives as ikk2 inhibitors
WO2010106016A1 (en)2009-03-172010-09-23Glaxo Group LimitedPyrimidine derivatives used as itk inhibitors
EP2408458A1 (en)2009-03-192012-01-25Merck Sharp&Dohme Corp.RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520684A (en)2009-03-192012-09-10メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of BTBandCNChomology1 (basic leucine zipper transcription factor 1) (Bach1) gene expression using small interfering nucleic acids (siNA)
EP2408915A2 (en)2009-03-192012-01-25Merck Sharp&Dohme Corp.RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408916A2 (en)2009-03-192012-01-25Merck Sharp&Dohme Corp.RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20110138223A (en)2009-03-272011-12-26머크 샤프 앤드 돔 코포레이션 RNA Interference-mediated Inhibition of Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acids (SINA)
US20120004281A1 (en)2009-03-272012-01-05Merck Sharp & Dohme CorpRNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411520A2 (en)2009-03-272012-02-01Merck Sharp&Dohme Corp.RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (en)2009-03-272012-09-20メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of apoptosis signal-regulated kinase 1 (ASK1) gene expression using small interfering nucleic acids (siNA)
EP2411019A2 (en)2009-03-272012-02-01Merck Sharp&Dohme Corp.RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2421834A1 (en)2009-04-242012-02-29Glaxo Group LimitedPyrazole and triazole carboxamides as crac channel inhibitors
WO2010122089A1 (en)2009-04-242010-10-28Glaxo Group LimitedN-pyrazolyl carboxamides as crac channel inhibitors
SI2424864T1 (en)2009-04-302015-03-31Glaxo Group LimitedOxazole substituted indazoles as pi3-kinase inhibitors
WO2010150014A1 (en)2009-06-242010-12-29Pulmagen Therapeutics (Inflammation) Limited5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en)2009-08-072013-03-05Novartis Ag3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (en)2009-08-122012-09-28Новартис Аг HETEROCYCLIC HYDRAZONES AND THEIR APPLICATION FOR THE TREATMENT OF CANCER AND INFLAMMATION
EA026693B1 (en)2009-08-172017-05-31Интелликайн ЭлЭлСиBenzoxazole and benzothiazole derivatives as pi3 kinase inhibitors
MX2012002179A (en)2009-08-202012-03-16Novartis AgHeterocyclic oxime compounds.
JP2013508414A (en)2009-10-222013-03-07バーテックス ファーマシューティカルズ インコーポレイテッド Compositions for the treatment of cystic fibrosis and other chronic diseases
GB0918922D0 (en)2009-10-282009-12-16Vantia LtdAminopyridine derivatives
GB0918924D0 (en)2009-10-282009-12-16Vantia LtdAzaindole derivatives
GB0918923D0 (en)2009-10-282009-12-16Vantia LtdAminothiazole derivatives
EP2507231A1 (en)2009-12-032012-10-10Glaxo Group LimitedIndazole derivatives as pi 3 - kinase inhibitors
EP2507226A1 (en)2009-12-032012-10-10Glaxo Group LimitedNovel compounds
JP2013512879A (en)2009-12-032013-04-18グラクソ グループ リミテッド Benzpyrazole derivatives as inhibitors of PI3 kinase
EP3020393B1 (en)2009-12-162020-10-073M Innovative Properties CompanyFormulations and methods for controlling mdi particle size delivery
WO2011098746A1 (en)2010-02-092011-08-18Pulmagen Therapeutics (Inflammation) LimitedCrystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en)2010-02-102010-03-31Argenta Therapeutics LtdRespiratory disease treatment
GB201002243D0 (en)2010-02-102010-03-31Argenta Therapeutics LtdRespiratory disease treatment
WO2011110575A1 (en)2010-03-112011-09-15Glaxo Group LimitedDerivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en)2010-03-192012-08-21Novartis AgPyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en)2010-04-292010-06-16Glaxo Group LtdNovel compounds
ES2548036T3 (en)2010-09-082015-10-13Glaxosmithkline Intellectual Property Development Limited Polymorphs and salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide
UY33597A (en)2010-09-092012-04-30Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
WO2012034095A1 (en)2010-09-092012-03-15Irm LlcCompounds and compositions as trk inhibitors
WO2012035055A1 (en)2010-09-172012-03-22Glaxo Group LimitedNovel compounds
US8372845B2 (en)2010-09-172013-02-12Novartis AgPyrazine derivatives as enac blockers
WO2012052459A1 (en)2010-10-212012-04-26Glaxo Group LimitedPyrazole compounds acting against allergic, inflammatory and immune disorders
JP5795643B2 (en)2010-10-212015-10-14グラクソ グループ リミテッドGlaxo Group Limited Pyrazole compounds acting on allergic, immune and inflammatory conditions
GB201018124D0 (en)2010-10-272010-12-08Glaxo Group LtdPolymorphs and salts
US20130324526A1 (en)2011-02-102013-12-05Novartis Ag[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en)2011-02-232016-08-10Intellikine, LLCHeterocyclic compounds and uses thereof
KR20140014184A (en)2011-02-252014-02-05아이알엠 엘엘씨Compounds and compositions as trk inhibitors
GB201104153D0 (en)2011-03-112011-04-27Glaxo Group LtdNovel compounds
EP2683716A1 (en)2011-03-112014-01-15Glaxo Group LimitedPyrido[3,4-b]pyrazine derivatives as syk inhibitors
UY34305A (en)2011-09-012013-04-30Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
EP2755976B1 (en)2011-09-152018-07-18Novartis AG6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
ES2882807T3 (en)2011-09-162021-12-02Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en)2011-09-162013-03-21Novartis AgPyridine/pyrazine amide derivatives
ES2558457T3 (en)2011-09-162016-02-04Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en)2011-09-162013-03-21Novartis AgPyridine amide derivatives
WO2013038373A1 (en)2011-09-162013-03-21Novartis AgPyridine amide derivatives
JP6130391B2 (en)2011-11-232017-05-17インテリカイン, エルエルシー Enhanced treatment regimen using MTOR inhibitors
US8809340B2 (en)2012-03-192014-08-19Novartis AgCrystalline form
WO2013149581A1 (en)2012-04-032013-10-10Novartis AgCombination products with tyrosine kinase inhibitors and their use
US9073921B2 (en)2013-03-012015-07-07Novartis AgSalt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en)2013-03-152014-09-25Intellikine, LlcCombination of kinase inhibitors and uses thereof
KR20160062179A (en)2013-10-172016-06-01글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드Pi3k inhibitor for treatment of respiratory disease
CA2925064A1 (en)2013-10-172015-04-23Glaxosmithkline Intellectual Property Development LimitedPi3k inhibitor for treatment of respiratory disease
WO2015084804A1 (en)2013-12-032015-06-11Novartis AgCombination of mdm2 inhibitor and braf inhibitor and their use
CN106458980A (en)2014-04-242017-02-22诺华股份有限公司Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
EA032075B1 (en)2014-04-242019-04-30Новартис АгAmino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160141856A (en)2014-04-242016-12-09노파르티스 아게Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
TW201625247A (en)2014-05-122016-07-16葛蘭素史密斯克藍智慧財產權有限公司Pharmaceutical compositions for treating infectious diseases
WO2016011658A1 (en)2014-07-252016-01-28Novartis AgCombination therapy
AU2015294889B2 (en)2014-07-312018-03-15Novartis AgCombination therapy
GB201602527D0 (en)2016-02-122016-03-30Glaxosmithkline Ip Dev LtdChemical compounds
US20190161480A1 (en)2016-08-082019-05-30Glaxosmithkline Intellectual Property Development LimitedChemical Compounds
GB201706102D0 (en)2017-04-182017-05-31Glaxosmithkline Ip Dev LtdChemical compounds
GB201712081D0 (en)2017-07-272017-09-13Glaxosmithkline Ip Dev LtdChemical compounds
WO2020250116A1 (en)2019-06-102020-12-17Novartis AgPyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
JOP20220044A1 (en)2019-08-282023-01-30Novartis Ag Hetero-substituted 1,3-phenylaryl derivatives and their use in the treatment of disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
ZW6584A1 (en)*1983-04-181985-04-17Glaxo Group LtdPhenethanolamine derivatives
GB2230525A (en)*1989-04-141990-10-24Glaxo Group Ltd1-(Hydroxyphenyl)-2-aminoethanol derivatives

Also Published As

Publication numberPublication date
WO2004039762A1 (en)2004-05-13
AU2003279338A1 (en)2004-05-25

Similar Documents

PublicationPublication DateTitle
GB0217225D0 (en)Medicinal compounds
GB0225540D0 (en)Medicinal compounds
GB0204719D0 (en)Medicinal compounds
GB0225535D0 (en)Medicinal compounds
GB0220730D0 (en)Medicinal compounds
GB0225030D0 (en)Medicinal compounds
GB0218625D0 (en)Pharmaceutical compounds
GB0324886D0 (en)Medicinal compounds
GB0303396D0 (en)Medicinal compounds
GB0215775D0 (en)Pharmaceutical compounds
GB0328490D0 (en)Medicinal compounds
AU2003215150A8 (en)Therapeutic compounds
GB0206505D0 (en)Pharmaceutical combination
GB0204392D0 (en)Pharmaceutical compound
GB0208392D0 (en)Therapeutic compounds
GB0224494D0 (en)Medicinal compounds
GB0225536D0 (en)Medicinal compounds
GB0225023D0 (en)Medicinal compounds
GB0225541D0 (en)Medicinal compounds
GB0225027D0 (en)Medicinal compounds
GB0225025D0 (en)Medicinal compounds
GB0225024D0 (en)Medicinal compounds
GB0228915D0 (en)Medicinal compounds
GB0224508D0 (en)Medicinal compounds
GB0225538D0 (en)Medicinal compounds

Legal Events

DateCodeTitleDescription
ATApplications terminated before publication under section 16(1)

[8]ページ先頭

©2009-2025 Movatter.jp